Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 10/20 | 0.46 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22799931 | 1.00 | FDPS (0.46) | FDPSGGPS1TSHRTHRBSMPD1 | |
| SCHEMBL19565503 | 0.80 | FDPS (0.43) | FDPSGGPS1TSHRTHRBSMPD1 | |
| SCHEMBL7939331 | 0.80 | FDPS (0.43) | FDPSGGPS1TSHRTHRBSMPD1 | |
| SCHEMBL4585292 | 0.80 | FDPS (0.47) | FDPSGGPS1SMPD1 | |
| SCHEMBL18874524 | 0.80 | FDPS (0.43) | FDPSGGPS1TSHRTHRBSMPD1 | |
| SCHEMBL31149403 | 0.80 | FDPS (0.47) | FDPSGGPS1SMPD1 | |
| SCHEMBL23467139 | 0.79 | FDPS (0.46) | FDPSGGPS1TSHRTHRBSMPD1 | |
| SCHEMBL28791871 | 0.79 | FDPS (0.46) | FDPSGGPS1TSHRTHRBSMPD1 | |
| SCHEMBL28791906 | 0.79 | FDPS (0.46) | FDPSGGPS1TSHRTHRBSMPD1 | |
| SCHEMBL28233886 | 0.79 | FDPS (0.46) | FDPSGGPS1TSHRTHRBSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392145-A1 | PROCESS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2020-12-17 | — | — | US | disclosed |
| US-10208054-B2 | Method of preparing buprenorphine | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2019-02-19 | — | — | US | disclosed |
| US-20170217978-A1 | METHOD OF PREPARING BUPRENORPHINE | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392145-A1 | PROCESS | C5, NUP205, NPM1 | FDPS 2857/4885GGPS1 2873/4885TSHR 2552/4885 |
| US-20170217978-A1 | METHOD OF PREPARING BUPRENORPHINE | OPRK1, OPRM1, OPRD1 | FDPS 2089/4885GGPS1 3395/4885TSHR 1905/4885 |
| US-10208054-B2 | Method of preparing buprenorphine | OPRK1, OPRM1, OPRD1 | FDPS 2089/4885GGPS1 3395/4885TSHR 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.